[HTML][HTML] Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
M Chianese, G Screm, F Salton, P Confalonieri… - Pharmaceuticals, 2024 - mdpi.com
Pirfenidone and Nintedanib are specific drugs used against idiopathic pulmonary fibrosis
(IPF) that showed efficacy in non-IPF fibrosing interstitial lung diseases (ILD). Both drugs …
(IPF) that showed efficacy in non-IPF fibrosing interstitial lung diseases (ILD). Both drugs …
[HTML][HTML] Computer-aided pulmonary fibrosis detection leveraging an advanced artificial intelligence triage and notification software
Background Improvement in recognition and referral of pulmonary fibrosis (PF) is vital to
improving patient outcomes within interstitial lung disease. We determined the performance …
improving patient outcomes within interstitial lung disease. We determined the performance …
[HTML][HTML] Beyond the Acute Phase: Long-Term Impact of COVID-19 on Functional Capacity and Prothrombotic Risk—A Pilot Study
Background and Objectives: Assessment of the prothrombotic, proinflammatory, and
functional status of a cohort of COVID-19 patients at least two years after the acute infection …
functional status of a cohort of COVID-19 patients at least two years after the acute infection …
[HTML][HTML] Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection–response to Guangting Zeng and Yuchi Zhou
We greatly appreciate Dr. Zeng and Dr. Zhou for their commentary which mentions that risk
factors for post-COVID pulmonary fibrosis include advanced age, disease severity, length of …
factors for post-COVID pulmonary fibrosis include advanced age, disease severity, length of …
Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection
G Zeng, Y Zhou - The Lancet Regional Health–Americas, 2023 - thelancet.com
As the pandemic progresses, the sequelaes of SARS-CoV-2 infection are causing concern
and alarm. Due to the high incidence of respiratory failure and the need for mechanical …
and alarm. Due to the high incidence of respiratory failure and the need for mechanical …
Effects of pharmacotherapy on post-COVID-19 pulmonary fibrosis: Systemic review
O Butranova, E Baybulatova, S Zyryanov… - BIO Web of …, 2024 - bio-conferences.org
Pulmonary fibrosis is one of serious consequences of COVID-19. Its prevalence and risk
factors including disease severity, length of mechanical ventilation and hospitalization were …
factors including disease severity, length of mechanical ventilation and hospitalization were …
[PDF][PDF] Prevalence and Risk Factors of Post-COVID-19 Pulmonary Fibrosis: A Meta-analysis
J Yanga, H Fengb, M Wangc, S Zhengd, N Aie - francis-press.com
COVID-19 is a global epidemic caused by severe acute respiratory syndrome coronavirus 2
infection. However, the understanding of long-term respiratory diseases in COVID-19 …
infection. However, the understanding of long-term respiratory diseases in COVID-19 …